

**Clinical trial results:  
A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with  
Lysosomal Acid Lipase Deficiency  
Summary**

EudraCT number	2011-004287-30
Trial protocol	DK ES GB IT DE BE HR NL
Global end of trial date	28 December 2017

**Results information**

Result version number	v1
This version publication date	21 July 2018
First version publication date	21 July 2018

**Trial information****Trial identification**

Sponsor protocol code	LAL-CL06
-----------------------	----------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02112994
WHO universal trial number (UTN)	U1111-1152-7171

Notes:

**Sponsors**

Sponsor organisation name	Alexion Pharmaceuticals Inc.
Sponsor organisation address	100 College St., New Haven, United States, 06510
Public contact	European Clinical Trial Information, Alexion Pharmaceuticals Inc., +33 147100606, clinicaltrials.eu@alexion.com
Scientific contact	European Clinical Trial Information, Alexion Pharmaceuticals Inc., +33 147100606, clinicaltrials.eu@alexion.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-001331-PIP01-12
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 April 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	28 December 2017
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study is to evaluate the safety and efficacy of sebelipase alfa in a broad population of participants with lysosomal acid lipase deficiency.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 June 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 1
Country: Number of subjects enrolled	Netherlands: 1
Country: Number of subjects enrolled	Spain: 8
Country: Number of subjects enrolled	Croatia: 2
Country: Number of subjects enrolled	Belgium: 4
Country: Number of subjects enrolled	Denmark: 1
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	Italy: 1
Country: Number of subjects enrolled	Brazil: 2
Country: Number of subjects enrolled	Canada: 1
Country: Number of subjects enrolled	Mexico: 4
Country: Number of subjects enrolled	Russian Federation: 1
Country: Number of subjects enrolled	Turkey: 1
Country: Number of subjects enrolled	United States: 3
Worldwide total number of subjects	31
EEA total number of subjects	18

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	16
Adolescents (12-17 years)	6
Adults (18-64 years)	9
From 65 to 84 years	0
85 years and over	0

---

## Subject disposition

### Recruitment

Recruitment details:

A total of 21 study centers were initiated in 15 countries, including Australia, Belgium, Brazil, Canada, Croatia, Denmark, Germany, Italy, Mexico, Netherlands, Russia, Spain, Turkey, United Kingdom (UK), and the United States. Seventeen study centers screened at least 1 participant in all of these countries, except the UK and the Netherlands.

### Pre-assignment

Screening details:

The study consisted of a screening period of up to 45 days. The maximum duration of a participant's participation in the study, inclusive of screening and follow-up visits, was approximately 155 weeks.

### Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

None (Open Label)

### Arms

Arm title	Sebelipase Alfa
-----------	-----------------

Arm description:

Participants initiated intravenous (IV) treatment with sebelipase alfa at a dose of 1 milligram (mg)/kilogram (kg) every other week (qow). Dose escalation to 3 mg/kg qow was considered if the participant met pre-defined dose-escalation criteria. A subsequent dose escalation to 3 mg/kg every week (qw) was considered if the participant continued to meet these criteria when receiving a dose of 3 mg/kg qow.

Arm type	Experimental
Investigational medicinal product name	Sebelipase Alfa
Investigational medicinal product code	
Other name	SBC-102
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

All eligible participants received repeat IV infusions of sebelipase alfa at an initial dose of 1 mg/kg qow. Sequential dose escalation to 3 mg/kg qow and 3 mg/kg qw was permitted based on evidence of disease progression. Dose decreases were permitted in the event of poor tolerability or in participants who achieved clinical stability on a dose of 3 mg/kg qw. Consecutive infusions were to be administered at least 7 days apart (for qow dosing) and at least 5 days apart (qw dosing).

Number of subjects in period 1	Sebelipase Alfa
Started	31
Completed	25
Not completed	6
Consent withdrawn by subject	2
Pregnancy	2
Liver transplant	1

Progressive disease	1
---------------------	---

## Baseline characteristics

### Reporting groups

Reporting group title	Sebelipase Alfa
-----------------------	-----------------

Reporting group description:

Participants initiated intravenous (IV) treatment with sebelipase alfa at a dose of 1 milligram (mg)/kilogram (kg) every other week (qow). Dose escalation to 3 mg/kg qow was considered if the participant met pre-defined dose-escalation criteria. A subsequent dose escalation to 3 mg/kg every week (qw) was considered if the participant continued to meet these criteria when receiving a dose of 3 mg/kg qow.

Reporting group values	Sebelipase Alfa	Total	
Number of subjects	31	31	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	16	16	
Adolescents (12-17 years)	6	6	
Adults (18-64 years)	9	9	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	16.92		
standard deviation	± 14.678	-	
Gender categorical			
Units: Subjects			
Female	12	12	
Male	19	19	
Ethnicity			
Units: Subjects			
Hispanic or Latino	6	6	
Not Hispanic or Latino	25	25	
Race			
Units: Subjects			
White	27	27	
Other	4	4	

## End points

### End points reporting groups

Reporting group title	Sebelipase Alfa
-----------------------	-----------------

Reporting group description:

Participants initiated intravenous (IV) treatment with sebelipase alfa at a dose of 1 milligram (mg)/kilogram (kg) every other week (qow). Dose escalation to 3 mg/kg qow was considered if the participant met pre-defined dose-escalation criteria. A subsequent dose escalation to 3 mg/kg every week (qw) was considered if the participant continued to meet these criteria when receiving a dose of 3 mg/kg qow.

Subject analysis set title	Full Analysis Set
----------------------------	-------------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

All participants who received at least 1 infusion of sebelipase alfa. The full analysis set was used for analysis of safety and efficacy.

Subject analysis set title	2-<4 Years
----------------------------	------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

This sub-group is part of the full analysis set and includes only those participants between the ages of 2 and less than 4 years old.

Subject analysis set title	4-18 Years
----------------------------	------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

This sub-group is part of the full analysis set and includes only those participants between the ages of 4 and 18 years old.

Subject analysis set title	>18 Years
----------------------------	-----------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

This sub-group is part of the full analysis set and includes only those participants greater than 18 years old.

Subject analysis set title	Pediatric Participants
----------------------------	------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

This sub-group is part of the full analysis set and includes only those participants 18 years old or younger.

### Primary: Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)

End point title	Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs) <sup>[1]</sup>
-----------------	---

End point description:

The number of participants experiencing severe TEAEs is presented for each age group who received sebelipase alfa in this open-label study. Information on adverse events (AEs) was obtained at each scheduled contact with the participant (or participant's parent or legal guardian), by specific questioning and, as appropriate, by examination. An AE was defined as any untoward medical occurrence in a participant that did not necessarily have to have a causal relationship with the administration of the study drug. An AE therefore could have been any unfavorable and unintended sign, symptom or disease temporally associated with the use of the study drug, whether or not considered related to the medicinal product. Pre-existing conditions that worsened in severity during the course of the study were reported as AEs. AEs were recorded from the date of informed consent until completion of the follow-up phone call at 4 weeks after the last infusion of sebelipase alfa administered.

End point type	Primary
----------------	---------

End point timeframe:

Week 144

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Quantitative statistical analyses were not conducted on any of the reported safety data.

<b>End point values</b>	2-<4 Years	4-18 Years	>18 Years	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	6	16	9	
Units: Participants	1	1	2	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percent Change In Serum Lipids From Baseline To Week 144

End point title	Percent Change In Serum Lipids From Baseline To Week 144
-----------------	--

End point description:

The effect of sebelipase alfa on lipid metabolism was evaluated by measuring the change from baseline to Week 144 in 4 serum lipids: low-density lipoprotein cholesterol (LDL-C); high-density lipoprotein cholesterol (HDL-C); non-HDL-C; triglycerides. Blood samples for these clinical laboratory tests were collected at scheduled time points and analyzed by a central laboratory.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 144

<b>End point values</b>	2-<4 Years	4-18 Years	>18 Years	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	5 <sup>[2]</sup>	12 <sup>[3]</sup>	2 <sup>[4]</sup>	
Units: Percent Change				
median (full range (min-max))				
LDL-C	-37.5 (-52 to -25)	-29.2 (-59 to 23)	-22.5 (-37 to -8)	
HDL-C	76.5 (30 to 132)	24.2 (-4 to 90)	6.1 (-10 to 22)	
Non-HDL-C	-39.1 (-53 to -29)	-26.7 (-62 to 19)	-22.1 (-33 to -11)	
Triglycerides	-48.3 (-61 to -11)	-15.8 (-74 to 112)	-22.0 (-25 to -19)	

Notes:

[2] - N=5 for all 4 measurements

[3] - N=12 for all 4 measurements

[4] - N=2 for all 4 measurements

## Statistical analyses

No statistical analyses for this end point

## Secondary: Participants Testing Positive For Anti-drug Antibodies (ADAs)

End point title	Participants Testing Positive For Anti-drug Antibodies (ADAs)
End point description:	
<p>The impact of ADAs on the safety and immunogenicity of sebelipase alfa was evaluated by testing for ADAs in participants who received sebelipase alfa in this open-label study. Blood samples for assessment were collected prior to study infusions at Week 2, Week 4, Week 8, Week 12, and every 12 weeks thereafter. Participants testing positive for ADAs were also tested for the presence of neutralizing antibodies that inhibited sebelipase alfa enzyme activity and/or cellular uptake. Any participant experiencing a moderate or severe infusion-associated reaction (IAR) was to have an additional assessment of ADAs at the next study visit (prior to study drug infusion); these participants were to also have serum samples collected at 1 to 2 hours after IAR onset and at the next study visit (prior to study drug infusion) for analysis of serum tryptase. The number of participants who became ADA positive and who tested positive for neutralizing antibodies are presented.</p>	
End point type	Secondary
End point timeframe:	
Week 144	

End point values	Sebelipase Alfa			
Subject group type	Reporting group			
Number of subjects analysed	31 <sup>[5]</sup>			
Units: Participants				
ADA Positive	2			
Neutralizing Antibodies Positive	0			

Notes:

[5] - Full Analysis Set

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change In Body Mass Index (BMI)-For-Age Percentile From Baseline To Week 144 in Pediatric Participants

End point title	Percent Change In Body Mass Index (BMI)-For-Age Percentile From Baseline To Week 144 in Pediatric Participants
End point description:	
<p>To evaluate the effects of sebelipase alfa on growth parameters in pediatric participants (<math>\leq 18</math> years old) presenting with evidence of growth delay, the percent change in the anthropometric parameter of BMI-for-age percentile from Baseline to Week 144 is reported. Anthropometric parameters were plotted on standard growth curves. When possible, historical data on growth parameters was also incorporated into the analyses. Percentiles and Z-scores for BMI-for-age were determined using standard growth charts appropriate to a participant's age on the date of the assessment: the World Health Organization standard growth chart for participants <math>\leq 2</math> years of age and the Centers for Disease Control standard growth chart for participants <math>&gt; 2</math> years of age.</p>	
End point type	Secondary
End point timeframe:	
Baseline, Week 144	

<b>End point values</b>	Pediatric Participants			
Subject group type	Subject analysis set			
Number of subjects analysed	17 <sup>[6]</sup>			
Units: Percent Change				
arithmetic mean (standard deviation)	26.45 (± 118.432)			

Notes:

[6] - Pediatric Participants (≤18 years old)

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change In Child-Pugh Status From Baseline To Week 144

End point title	Percent Change In Child-Pugh Status From Baseline To Week 144			
End point description:	<p>In order to evaluate the effects of sebelipase alfa on liver function, the change in Child-Pugh status from Baseline to Week 144 for participants with Child-Pugh class C or B at Baseline is reported. The Child-Pugh score is used in clinical practice to assess prognosis in individuals with chronic liver disease. Laboratory data were used in derivation of the score by summing individual scores from clinical laboratory test results and physical examinations, including total serum bilirubin, serum albumin, prothrombin time, ascites, and hepatic encephalopathy. The total score was used to determine the Child-Pugh classification, which was reported as Class A (score of 5 or 6), Class B (score of 7 to 9) or Class C (score of 10 to 15). Higher scores and higher categories represented a worse outcome. Data is reported for the 18 participants with follow-up data at Week 144.</p>			
End point type	Secondary			
End point timeframe:	Baseline, Week 144			

<b>End point values</b>	Sebelipase Alfa			
Subject group type	Reporting group			
Number of subjects analysed	18 <sup>[7]</sup>			
Units: Percent Change				
arithmetic mean (standard deviation)	3.9 (± 7.68)			

Notes:

[7] - Full Analysis Set

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Screening (up to 45 days prior to start of treatment) to Week 144.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

### Reporting groups

Reporting group title	2-<4 Years
-----------------------	------------

Reporting group description:

This sub-group is part of the full analysis set and includes only those participants between the ages of 2 and less than 4 years old.

Reporting group title	4-18 Years
-----------------------	------------

Reporting group description:

This sub-group is part of the full analysis set and includes only those participants between the ages of 4 and 18 years old.

Reporting group title	>18 Years
-----------------------	-----------

Reporting group description:

This sub-group is part of the full analysis set and includes only those participants greater than 18 years old.

<b>Serious adverse events</b>	2-<4 Years	4-18 Years	>18 Years
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 6 (16.67%)	4 / 16 (25.00%)	5 / 9 (55.56%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Clavicle fracture			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Shock			

subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Surgical and medical procedures</b>			
Liver transplant			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Immune system disorders</b>			
Anaphylactic reaction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
Abdominal pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	2 / 9 (22.22%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain lower			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatobiliary disorders</b>			
Hepatic function abnormal			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Respiratory, thoracic and mediastinal disorders</b>			
Pneumothorax			

subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Pneumonia			
subjects affected / exposed	0 / 6 (0.00%)	2 / 16 (12.50%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Product issues</b>			
Device breakage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
Fluid overload			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	2-<4 Years	4-18 Years	>18 Years
<b>Total subjects affected by non-serious adverse events</b>			
subjects affected / exposed	6 / 6 (100.00%)	15 / 16 (93.75%)	9 / 9 (100.00%)
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
Gastrointestinal lymphoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Hepatic neoplasm			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Papilloma			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Skin papilloma			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 5	0 / 9 (0.00%) 0
Vascular disorders			
Haematoma			
subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	2 / 16 (12.50%) 5	0 / 9 (0.00%) 0
Hypotension			
subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	2 / 9 (22.22%) 2
Hot flush			
subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
Orthostatic hypotension			
subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed occurrences (all)	4 / 6 (66.67%) 8	8 / 16 (50.00%) 16	5 / 9 (55.56%) 7
Fatigue			
subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 2	1 / 16 (6.25%) 1	1 / 9 (11.11%) 1
Catheter site erythema			
subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Catheter site extravasation			
subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 4	0 / 9 (0.00%) 0
Catheter site related reaction			
subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Cyst			
subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Extravasation			

subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Facial pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Hyperthermia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Hypothermia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	6	0	0
Influenza like illness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Infusion site pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Malaise			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Microlithiasis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Peripheral swelling			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Vaccination site erythema			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Vaccination site reaction			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Vessel puncture site bruise			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
Vessel puncture site reaction subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
Immune system disorders			
Allergy to arthropod bite subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Anaphylactic shock subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
Seasonal allergy subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Reproductive system and breast disorders			
Balanoposthitis subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
Dysmenorrhoea subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 2	3 / 16 (18.75%) 8	4 / 9 (44.44%) 5
Epistaxis subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 3	5 / 16 (31.25%) 32	0 / 9 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	2 / 16 (12.50%) 2	2 / 9 (22.22%) 2
Catarrh subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 3	2 / 16 (12.50%) 4	0 / 9 (0.00%) 0
Rhinorrhoea			

subjects affected / exposed	1 / 6 (16.67%)	2 / 16 (12.50%)	0 / 9 (0.00%)
occurrences (all)	2	6	0
Bronchospasm			
subjects affected / exposed	0 / 6 (0.00%)	2 / 16 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	3	0
Dyspnoea			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Rhinitis allergic			
subjects affected / exposed	1 / 6 (16.67%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	2	5	0
Allergic cough			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Dry throat			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Dysphonia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Nasal congestion			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Sneezing			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Tonsillar hypertrophy			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract congestion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Wheezing			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Product issues			
Device infusion issue subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 2	0 / 9 (0.00%) 0
Investigations			
Body temperature increased subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 2	1 / 16 (6.25%) 2	1 / 9 (11.11%) 1
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	2 / 9 (22.22%) 4
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 3
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 4
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 3
Blood cholesterol increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Blood pressure increased subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 3	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
C-reactive protein increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Haemoglobin decreased			

subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Low density lipoprotein increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Protein total decreased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 6 (16.67%)	4 / 16 (25.00%)	1 / 9 (11.11%)
occurrences (all)	3	8	1
Limb injury			
subjects affected / exposed	1 / 6 (16.67%)	1 / 16 (6.25%)	1 / 9 (11.11%)
occurrences (all)	1	1	1
Bone contusion			
subjects affected / exposed	1 / 6 (16.67%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Face injury			
subjects affected / exposed	0 / 6 (0.00%)	2 / 16 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Animal scratch			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Arthropod bite			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	3	0	0
Concussion			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Craniocerebral injury			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Ear canal injury			

subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Foot fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Forearm fracture			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Head injury			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Laceration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Ligament sprain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Procedural pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Radius fracture			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Scratch			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Skin abrasion			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Sports injury			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Wound			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Congenital, familial and genetic			

disorders			
Gilbert's syndrome			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Glucose-6-phosphate dehydrogenase deficiency			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Von Willebrand's disease			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Left ventricular dilatation			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Left ventricular hypertrophy			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 6 (16.67%)	6 / 16 (37.50%)	3 / 9 (33.33%)
occurrences (all)	1	12	14
Dizziness			
subjects affected / exposed	1 / 6 (16.67%)	1 / 16 (6.25%)	1 / 9 (11.11%)
occurrences (all)	1	1	2
Central nervous system lesion			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hypoaesthesia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Lethargy			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Migraine			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	5

Post-traumatic headache subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
Presyncope subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
<b>Blood and lymphatic system disorders</b>			
Anaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Iron deficiency anaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Lymphadenopathy subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 6	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
Macrocytosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Splenic cyst subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
<b>Ear and labyrinth disorders</b>			
Hypoacusis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
<b>Eye disorders</b>			
Astigmatism subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Conjunctival hyperaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
Dark circles under eyes			

subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Dry eye			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Eye allergy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Hypermetropia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Scleral discolouration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Visual impairment			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Xerophthalmia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	3 / 6 (50.00%)	4 / 16 (25.00%)	6 / 9 (66.67%)
occurrences (all)	8	9	11
Abdominal pain			
subjects affected / exposed	3 / 6 (50.00%)	4 / 16 (25.00%)	4 / 9 (44.44%)
occurrences (all)	5	6	8
Vomiting			
subjects affected / exposed	1 / 6 (16.67%)	5 / 16 (31.25%)	4 / 9 (44.44%)
occurrences (all)	6	11	6
Abdominal pain upper			
subjects affected / exposed	2 / 6 (33.33%)	2 / 16 (12.50%)	2 / 9 (22.22%)
occurrences (all)	3	4	3
Constipation			
subjects affected / exposed	0 / 6 (0.00%)	2 / 16 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	4	2

Nausea			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	2 / 9 (22.22%)
occurrences (all)	0	1	7
Dental caries			
subjects affected / exposed	1 / 6 (16.67%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Gastritis			
subjects affected / exposed	1 / 6 (16.67%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	1	2	0
Gingival bleeding			
subjects affected / exposed	1 / 6 (16.67%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Toothache			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	1 / 9 (11.11%)
occurrences (all)	0	1	2
Anal fissure			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Ascites			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Dyspepsia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Frequent bowel movements			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Functional gastrointestinal disorder			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Gastric varices			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0

Gastrointestinal disorder			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Gingival swelling			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Haematochezia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Lip swelling			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Odynophagia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Oral contusion			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Tongue eruption			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Hepatic calcification			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Hepatic fibrosis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Liver tenderness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			

Ecchymosis			
subjects affected / exposed	1 / 6 (16.67%)	3 / 16 (18.75%)	0 / 9 (0.00%)
occurrences (all)	5	25	0
Dermatitis			
subjects affected / exposed	1 / 6 (16.67%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Eczema			
subjects affected / exposed	1 / 6 (16.67%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	7	1	0
Erythema			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Petechiae			
subjects affected / exposed	0 / 6 (0.00%)	2 / 16 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	3	0
Rash			
subjects affected / exposed	1 / 6 (16.67%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	8	1	0
Rash papular			
subjects affected / exposed	0 / 6 (0.00%)	2 / 16 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Skin lesion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	2 / 9 (22.22%)
occurrences (all)	0	0	2
Urticaria			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	1 / 9 (11.11%)
occurrences (all)	0	2	9
Acne			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Blister			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Dermatitis allergic			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0

Dermatitis contact subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
Dry skin subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
Generalised erythema subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 2	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
Haemorrhage subcutaneous subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
Miliaria subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
Photosensitivity reaction subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
Pruritus allergic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Rash pruritic subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
Rosacea subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
Skin discolouration subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Skin reaction subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Renal and urinary disorders Urinary incontinence			

subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
Bladder dysfunction subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
Calculus urinary subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
Crystalluria subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
Leukocyturia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Endocrine disorders Delayed puberty subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	1 / 9 (11.11%) 1
Back pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	2 / 16 (12.50%) 3	0 / 9 (0.00%) 0
Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	1 / 9 (11.11%) 1
Joint effusion subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
Myalgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
Spinal pain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Temporomandibular joint surgery			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
<b>Infections and infestations</b>			
<b>Nasopharyngitis</b>			
subjects affected / exposed	3 / 6 (50.00%)	6 / 16 (37.50%)	5 / 9 (55.56%)
occurrences (all)	8	16	15
<b>Upper respiratory tract infection</b>			
subjects affected / exposed	1 / 6 (16.67%)	5 / 16 (31.25%)	4 / 9 (44.44%)
occurrences (all)	3	6	4
<b>Gastroenteritis</b>			
subjects affected / exposed	1 / 6 (16.67%)	3 / 16 (18.75%)	3 / 9 (33.33%)
occurrences (all)	1	6	5
<b>Pharyngitis</b>			
subjects affected / exposed	2 / 6 (33.33%)	5 / 16 (31.25%)	0 / 9 (0.00%)
occurrences (all)	4	5	0
<b>Respiratory tract infection</b>			
subjects affected / exposed	3 / 6 (50.00%)	3 / 16 (18.75%)	1 / 9 (11.11%)
occurrences (all)	10	5	1
<b>Conjunctivitis</b>			
subjects affected / exposed	1 / 6 (16.67%)	1 / 16 (6.25%)	2 / 9 (22.22%)
occurrences (all)	1	1	2
<b>Bronchitis</b>			
subjects affected / exposed	1 / 6 (16.67%)	1 / 16 (6.25%)	1 / 9 (11.11%)
occurrences (all)	1	2	1
<b>Ear infection</b>			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	2 / 9 (22.22%)
occurrences (all)	1	0	2
<b>Eye infection</b>			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	2 / 9 (22.22%)
occurrences (all)	2	0	3
<b>Influenza</b>			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	2 / 9 (22.22%)
occurrences (all)	1	0	4

Oral herpes			
subjects affected / exposed	0 / 6 (0.00%)	2 / 16 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	2	1
Otitis media acute			
subjects affected / exposed	0 / 6 (0.00%)	3 / 16 (18.75%)	0 / 9 (0.00%)
occurrences (all)	0	3	0
Rhinitis			
subjects affected / exposed	1 / 6 (16.67%)	2 / 16 (12.50%)	0 / 9 (0.00%)
occurrences (all)	1	10	0
Sinusitis			
subjects affected / exposed	0 / 6 (0.00%)	2 / 16 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	2	2
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	2 / 9 (22.22%)
occurrences (all)	0	1	2
Acute sinusitis			
subjects affected / exposed	0 / 6 (0.00%)	2 / 16 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	4	0
Gastroenteritis viral			
subjects affected / exposed	2 / 6 (33.33%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	6	0	0
Hordeolum			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Pharyngotonsillitis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Respiratory tract infection viral			
subjects affected / exposed	2 / 6 (33.33%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	7	0	0
Tonsillitis			
subjects affected / exposed	1 / 6 (16.67%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Viral infection			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	2	0	1

Viral upper respiratory tract infection			
subjects affected / exposed	2 / 6 (33.33%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	4	0	0
Adenoiditis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Clostridial infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Device related infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Folliculitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Gastritis viral			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal protozoal infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Giardiasis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Gingivitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Groin abscess			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Herpangina			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0

Impetigo			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Infective glossitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Lower respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Molluscum contagiosum			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Oral fungal infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Pharyngitis streptococcal			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Pyelonephritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Rash pustular			
subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Rotavirus infection			
subjects affected / exposed	1 / 6 (16.67%)	0 / 16 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Sepsis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Soft tissue infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Subcutaneous abscess			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1

Tonsillitis streptococcal subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Tooth infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 2
Tracheitis subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
Varicella zoster virus infection subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
Metabolism and nutrition disorders			
Vitamin D deficiency subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2	4 / 16 (25.00%) 5	0 / 9 (0.00%) 0
Iron deficiency subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	2 / 16 (12.50%) 2	0 / 9 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Dyslipidaemia subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 16 (0.00%) 0	0 / 9 (0.00%) 0
Folate deficiency subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
Hyperlipidaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 16 (0.00%) 0	1 / 9 (11.11%) 1
Hypomagnesaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 16 (6.25%) 1	0 / 9 (0.00%) 0
Overweight			

subjects affected / exposed	0 / 6 (0.00%)	1 / 16 (6.25%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Vitamin B12 deficiency			
subjects affected / exposed	0 / 6 (0.00%)	0 / 16 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
02 February 2015	<ul style="list-style-type: none"><li>- Removed 'seroconversion rate' and 'time to seroconversion' from the immunogenicity outcome variables. The intent was to characterize ADAs for all isotypes. In this study, a participant was considered to be ADA positive if they had at least 1 positive ADA titer at any time during the study. However, a single positive ADA result would not necessarily imply that a participant had seroconverted. Moreover, analysis of tolerization (for which no standard definition exists) would not be appropriate to these circumstances.</li><li>- Limited liver biopsy by the transjugular method to participants with advanced liver disease (as local facilities permitted), rather than recommending this for all study participants.</li><li>- Updated the guidance on the management of IARs based on clinical experience in other ongoing studies with sebelipase alfa.</li><li>- Clarified that AEs collected during hospitalization would be assessed and reported.</li><li>- Clarified that AEs occurring after signing the informed consent but before the first dose of study drug would only be recorded if deemed related to study procedures or requirements.</li></ul>
07 December 2015	<ul style="list-style-type: none"><li>- Clarified that the minimum duration of treatment would be "at least 52 weeks." This clarification was added in response to Pediatric Committee comments on the paediatric investigation plan RfM.</li><li>- Added a PK profile for participants receiving a dose decrease (the protocol already required a PK profile for participants receiving a dose increase), and added an ADA assessment prior to the first infusion at the new dose for all participants receiving a dose modification (increase or decrease). These additional data will support an evaluation of the relationship between immunogenicity, sebelipase alfa exposure, and clinical response during long-term treatment with sebelipase alfa.</li></ul>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported